FibroGen logo

FibroGenNASDAQ: FGEN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 November 2014

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$31.25 M
-98%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
15%vs. sector
-98%vs. 3y high
5%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:28:03 GMT
$0.31+$0.00(+0.42%)

Dividend

No data over the past 3 years
$50.64 M$34.76 M
$50.64 M-$15.54 M

Analysts recommendations

Institutional Ownership

FGEN Latest News

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript
seekingalpha.com09 August 2024 Sentiment: NEUTRAL

FibroGen, Inc. (NASDAQ:FGEN ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David DeLucia - CFA Vice President, Corporate FP&A & Investor Relations Thane Wettig - Chief Executive Officer Deyaa Adib - Chief Medical Officer Juan Graham - Chief Financial Officer Chris Chung - Senior Vice President, China Operations Conference Call Participants Dalton Greenwood - William Blair Dina Ramadane - Bank of America Paul Choi - Goldman Sachs Operator Good day and welcome to the FibroGen Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.

FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
zacks.com06 August 2024 Sentiment: POSITIVE

FibroGen (FGEN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.65 per share a year ago.

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
globenewswire.com03 June 2024 Sentiment: POSITIVE

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen's immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron's anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors.

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
globenewswire.com03 June 2024 Sentiment: POSITIVE

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression.

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
globenewswire.com23 May 2024 Sentiment: POSITIVE

SAN FRANCISCO, May 23, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study conducted by the University of California San Francisco of FG-3246 (FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with a MMAE-containing payload, in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

3 Nightmare Nasdaq Stocks Not Worth Holding Another Day
InvestorPlace20 March 2024 Sentiment: NEGATIVE

Stocks are at the mercy of many factors, and often, prices are just a poor earnings report or a negative headline away from a significant drop. There are times when nobody has any way of preparing.

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript
Seeking Alpha06 November 2023 Sentiment: POSITIVE

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research06 November 2023 Sentiment: POSITIVE

The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

7 Stocks to Sell Before the Axe Falls
InvestorPlace19 October 2023 Sentiment: NEGATIVE

While a contentious topic, investors seeking long-term success must frequently consider stocks to sell. Similar to changing the oil in a combustion-powered car, you've got to keep the overall machinery running well.

FibroGen stock plummets as muscular dystrophy drug trial fails
Proactive Investors30 August 2023 Sentiment: NEGATIVE

FibroGen Inc (NASDAQ:FGEN) plummeted some 27% lower in Wednesday's early deals after revealing that its intended treatment for Duchenne muscular dystrophy failed to achieve primary and secondary endpoints in a clinical study. In the trial, the potential drug, pamrevlumab, had targeted an improvement in an ambulatory assessment score at 52 weeks in boys with DMD, ages six through 11.

  • 1(current)
  • 2

What type of business is FibroGen?

FibroGen, Inc. is a biopharmaceutical company that discovers, develops, and commercializes a range of innovative therapeutic products for the treatment of anemia, fibrotic diseases, and cancer. The company was founded in 1993. Its corporate and research divisions are located in San Francisco, California. FibroGen Inc. has two leading clinical development candidates: Roxadustat - used in the treatment of anemia in chronic kidney disease, myelodysplastic syndromes, and anemia induced by chemotherapy. Pamrevlumab - for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy. None of the company's products have reached the stage of commercial sales.

What sector is FibroGen in?

FibroGen is in the Healthcare sector

What industry is FibroGen in?

FibroGen is in the Biotechnology industry

What country is FibroGen from?

FibroGen is headquartered in United States

When did FibroGen go public?

FibroGen initial public offering (IPO) was on 14 November 2014

What is FibroGen website?

https://www.fibrogen.com

Is FibroGen in the S&P 500?

No, FibroGen is not included in the S&P 500 index

Is FibroGen in the NASDAQ 100?

No, FibroGen is not included in the NASDAQ 100 index

Is FibroGen in the Dow Jones?

No, FibroGen is not included in the Dow Jones index

When was FibroGen the previous earnings report?

No data

When does FibroGen earnings report?

The next expected earnings date for FibroGen is 06 November 2024